Kynamro (Genzyme Corporation)
Welcome to the PulseAid listing for the Kynamro drug offered from Genzyme Corporation. This Apolipoprotein B-100 Synthesis Inhibitor [EPC],Decreased Protein Synthesis [PE],Antisense Oligonucleotide [EPC],Oligonucleotides, Antisense [Chemical/Ingredient] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
| LABELER NAME / MANUFACTURER: | Genzyme Corporation |
| NON-PROPRIETARY NAME: | MIPOMERSEN SODIUM |
| SUBSTANCE NAME: | MIPOMERSEN SODIUM |
| TYPE: | HUMAN PRESCRIPTION DRUG |
| PHARMA CLASS: | Apolipoprotein B-100 Synthesis Inhibitor [EPC],Decreased Protein Synthesis [PE],Antisense Oligonucleotide [EPC],Oligonucleotides, Antisense [Chemical/Ingredient] |
| ROUTE: | SUBCUTANEOUS |
| DOSAGE FORM: | INJECTION, SOLUTION |
| MARKETING CATEGORY NAME: | NDA |
| START MARKETING DATE: | 2013-01-29 |
| END MARKETING DATE: | 0000-00-00 |
Kynamro HUMAN PRESCRIPTION DRUG Details:
| Item Description | Kynamro from Genzyme Corporation |
| LABELER NAME: | Genzyme Corporation |
| DEA SCHEDULE: |
|
| ACTIVE STRENGTH: | 200(mg/mL) |
| START MARKETING DATE: | 2013-01-29 |
| END MARKETING DATE: | 0000-00-00 |
| PRODUCT ID: | 58468-0191_37da4828-7c56-43a3-9c21-8781d5e7d0d2 |
| PRODUCT NDC: | 58468-0191 |
| APPLICATION NUMBER: | NDA203568 |
Other MIPOMERSEN SODIUM Pharmaceutical Manufacturers / Labelers:
